FRX vs. SLS, CRON, TEV, ABT, NOT, PYR, NVO, TLRY, DNA, and VBV
Should you be buying Fennec Pharmaceuticals stock or one of its competitors? The main competitors of Fennec Pharmaceuticals include Solaris Resources (SLS), Cronos Group (CRON), Tervita (TEV), Absolute Software Co. (ABT.TO) (ABT), Noront Resources (NOT), PyroGenesis Canada Inc. (PYR.V) (PYR), Novo Resources Corp. (NVO.V) (NVO), Tilray Brands (TLRY), Dalradian Resources (DNA), and VBI Vaccines (VBV). These companies are all part of the "pharmaceutical products" industry.
Fennec Pharmaceuticals vs. Its Competitors
Solaris Resources (TSE:SLS) and Fennec Pharmaceuticals (TSE:FRX) are both small-cap pharmaceutical products companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, media sentiment, profitability, earnings, institutional ownership and dividends.
Solaris Resources has a beta of 1.9, meaning that its share price is 90% more volatile than the S&P 500. Comparatively, Fennec Pharmaceuticals has a beta of 0.25, meaning that its share price is 75% less volatile than the S&P 500.
Solaris Resources has a net margin of 0.00% compared to Fennec Pharmaceuticals' net margin of -2.30%. Fennec Pharmaceuticals' return on equity of 29.94% beat Solaris Resources' return on equity.
Fennec Pharmaceuticals has higher revenue and earnings than Solaris Resources. Fennec Pharmaceuticals is trading at a lower price-to-earnings ratio than Solaris Resources, indicating that it is currently the more affordable of the two stocks.
Solaris Resources currently has a consensus price target of C$12.50, suggesting a potential upside of 72.65%. Given Solaris Resources' higher possible upside, research analysts clearly believe Solaris Resources is more favorable than Fennec Pharmaceuticals.
25.1% of Solaris Resources shares are owned by institutional investors. Comparatively, 52.8% of Fennec Pharmaceuticals shares are owned by institutional investors. 40.6% of Solaris Resources shares are owned by insiders. Comparatively, 16.2% of Fennec Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
In the previous week, Solaris Resources' average media sentiment score of 0.00 equaled Fennec Pharmaceuticals'average media sentiment score.
Summary
Fennec Pharmaceuticals beats Solaris Resources on 8 of the 14 factors compared between the two stocks.
Get Fennec Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for FRX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding FRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Fennec Pharmaceuticals Competitors List
Related Companies and Tools
This page (TSE:FRX) was last updated on 8/10/2025 by MarketBeat.com Staff
